

ASX RELEASE | OSTEOPORE LIMITED

CHANGE OF SHARE REGISTRY DETAILS

23 June 2023: Osteopore Limited (ASX: OSX) (“Osteopore” or the “Company”), a global leader in the manufacture of innovative regenerative implants that empower natural tissue regeneration, advises that as of Monday, 26 June 2023, the Company has changed its provider for shareholder registry services from Link Market Services to Automic Pty Ltd (“Automic”).

Our new Share registry contact details are as follows:

Automic
Level 5, 126 Phillip Street
Sydney NSW 2000

GPO Box 5193
Sydney NSW 2001

Shareholders can easily and efficiently manage their holdings via Automic’s secure and highly accessible online investor portal. The portal provides, among other things, an online interface to update and manage shareholder details, view balances and transaction history.

Shareholder registration online

Shareholders that are not already a user of Automic’s investor portal may visit <https://investor.automic.com.au> and signup to register their details using the two simple steps provided in the setup process.

Shareholders with any queries in relation to their Osteopore Limited holding are advised to contact Automic at hello@automicgroup.com.au or on 1300 288 664 (within Australia) or +61 2 9698 5414 (outside Australia).

This announcement was authorised for release by the Company Secretary of Osteopore Limited.

For more information, please contact:

Mark Leong

Executive Chairman
Osteopore Limited
+65 9011 7009

Mark_Leong@osteopore.com

About Osteopore Limited

Osteopore Ltd is an Australian and Singapore based medical technology company commercialising a range of products specifically engineered to facilitate natural bone healing across multiple therapeutic areas. Osteopore's patented technology fabricates specific micro-structured scaffolds for bone regeneration through 3D printing and bioresorbable material.

Osteopore's patent-protected scaffolds are manufactured using a proprietary manufacturing technique with a polymer that naturally dissolve over time to leave only natural, healthy bone tissue, significantly reducing post-surgery complications commonly associated with permanent bone implants. Our 3D printer technology is not available in the market and unique to Osteopore.

Forward-Looking Statements

Statements contained in this release, particularly those regarding possible or assumed future performance, revenue, costs, dividends, production levels or rates, prices, or potential growth of Osteopore Limited, are, or may be, forward-looking statements. Such statements relate to future events and expectations and, as such, involve known and unknown risks and uncertainties. Actual results may differ materially from those expressed or implied by these forward-looking statements depending on various factors.